Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.12 Insider Own3.80% Shs Outstand178.13M Perf Week-1.42%
Market Cap126.44M Forward P/E- EPS next Y-0.10 Insider Trans- Shs Float155.44M Perf Month-0.03%
Income-19.30M PEG- EPS next Q-0.02 Inst Own8.40% Short Float4.30% Perf Quarter-2.77%
Sales- P/S- EPS this Y-16.70% Inst Trans0.03% Short Ratio6.23 Perf Half Y-31.75%
Book/sh0.17 P/B4.18 EPS next Y23.10% ROA-66.20% Target Price3.17 Perf Year47.88%
Cash/sh0.21 P/C3.31 EPS next 5Y- ROE-95.00% 52W Range0.37 - 1.85 Perf YTD39.18%
Dividend- P/FCF- EPS past 5Y4.90% ROI- 52W High-61.63% Beta1.10
Dividend %- Quick Ratio26.10 Sales past 5Y- Gross Margin- 52W Low91.84% ATR0.05
Employees16 Current Ratio26.10 Sales Q/Q- Oper. Margin- RSI (14)43.53 Volatility5.08% 5.96%
OptionableNo Debt/Eq0.00 EPS Q/Q100.00% Profit Margin- Rel Volume0.59 Prev Close0.72
ShortableYes LT Debt/Eq0.00 EarningsNov 04 Payout- Avg Volume1.07M Price0.71
Recom2.00 SMA20-6.61% SMA50-4.26% SMA200-23.50% Volume629,209 Change-1.42%
28-Dec-12Initiated Burrill Institutional Research Mkt Outperform $1
18-Jan-12Resumed Rodman & Renshaw Mkt Perform
16-Jun-11Resumed Brean Murray Buy $3
02-Dec-10Initiated Brean Murray Buy $3
03-Oct-14 04:24PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
30-Sep-14 09:00AM  Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum GlobeNewswire
26-Sep-14 07:54AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Zacks
24-Sep-14 04:30PM  Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer GlobeNewswire
23-Sep-14 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland GlobeNewswire
16-Sep-14 09:00AM  Rexahn Pharmaceuticals to Present at the BioPharm America 2014 in Boston, Massachusetts, USA Business Wire
04-Sep-14 09:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014 Business Wire +7.79%
06:48AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% Zacks
03-Sep-14 09:00AM  Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform Business Wire +10.00%
22-Aug-14 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
14-Aug-14 09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update Business Wire -5.48%
13-Aug-14 04:33PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
18-Jul-14 09:00AM  Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors Business Wire
16-Jun-14 06:52AM  What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) Zacks
09-Jun-14 04:21PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
23-May-14 04:41PM  Rexahn files $150M mixed securities shelf at theflyonthewall.com
16-May-14 08:25AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% Zacks
15-May-14 09:08AM  Rexahn sees cash, cash equivalents balance sufficient to fund company into 1H16 at theflyonthewall.com +19.77%
09:06AM  Rexahn reports Q1 EPS (9c), consensus (2c) at theflyonthewall.com
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update Business Wire
14-May-14 05:08PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online +8.86%
05:07PM  Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification at Seeking Alpha
08-May-14 09:04AM  Rexahn announces additional RX-3117 preclinical studies data at theflyonthewall.com
09:00AM  Rexahn Announces Additional Data from Preclinical Studies of RX-3117 Business Wire
21-Apr-14 04:23PM  Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff at Seeking Alpha
09:01AM  Rexahn presents data from preclinical studies of RX-21101 theflyonthewall.com
09:00AM  Rexahn Presents Data from Preclinical Studies of RX-21101 Business Wire
02-Apr-14 09:00AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting Business Wire +12.28%
24-Mar-14 08:15AM  Rexahn sees complete RX-3117 Phase I enrollment in 4Q14-early FY15 theflyonthewall.com
08:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights Business Wire
21-Mar-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online
19-Mar-14 06:00AM  3 Stocks Under $10 Making Big Moves at TheStreet
17-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Business Wire
15-Mar-14 03:15PM  This Week in Biotech: NW Bio Soars While Geron Goes Geronimo at Motley Fool
12-Mar-14 04:30PM  Phase I Data on Rexahn's Supinoxin Zacks
11-Mar-14 02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher at Motley Fool
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors Business Wire
07-Mar-14 10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet -8.33%
04-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference Business Wire
03-Mar-14 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Optionetics +5.19%
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Business Wire
27-Feb-14 12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket at Seeking Alpha +10.66%
06-Feb-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet +7.77%
04-Feb-14 08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Business Wire
31-Jan-14 02:16PM  Following Unmet Needs To Biotech Profits: Echo He at Seeking Alpha
27-Jan-14 02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3% Zacks
21-Jan-14 04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 at TheStreet
15-Jan-14 03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility at Seeking Alpha -10.34%
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
08:59AM  Rexahn Announces $20 Million Registered Direct Offering Business Wire
08:26AM  3 Biotechs Getting Plenty Of Attention From Investors at Seeking Alpha
14-Jan-14 09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma Business Wire -27.50%
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
10-Jan-14 10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today at TheStreet +62.86%
09-Jan-14 04:20PM  Rexahn Pharma rises as analyst starts coverage AP +12.90%
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial at Seeking Alpha
08-Jan-14 08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors Business Wire +5.08%
07-Jan-14 08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 Business Wire +5.36%
22-Dec-13 12:49PM  Rexahn: A Turn Around Story For 2014 at Seeking Alpha
11-Dec-13 08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902) Business Wire +20.00%
25-Nov-13 01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment at Seeking Alpha +5.26%
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ahn Chang HoDirectorJun 12Option Exercise0.80136,193108,9546,950,117Jun 16 07:48 PM
Ahn Chang HoDirectorJun 12Sale0.99136,193134,4366,813,924Jun 16 07:48 PM
McIntosh David MDirectorApr 14Option Exercise0.80125,000100,000125,000Apr 16 04:18 PM